Clinical Report: Spatial RNA Velocity Analysis in Melanoma Microenvironment

Overview

This study presents a novel computational framework for spatial RNA velocity analysis, utilizing nuclear and cytoplasmic RNA localization to infer transcriptional dynamics in melanoma. The findings reveal significant associations between dynamic genes and patient prognosis.

Background

Melanoma exhibits significant cellular heterogeneity and immune infiltration, which are critical for understanding tumor progression and treatment responses. Traditional RNA velocity analysis has been limited by the lack of spliced/unspliced mRNA counts in spatial transcriptomics. This research addresses that gap.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• Developed a framework that uses nuclear and cytoplasmic RNA as proxies for unspliced and spliced mRNA.
• Successfully reconstructed progression trajectories of melanoma cells and T cell differentiation paths.
• Identified cluster-specific dynamic genes significantly associated with patient prognosis.
• Dynamic genes formed protein-protein interaction networks enriched for immune-related pathways.
• Provided a computational strategy to decode spatiotemporal dynamics from static spatial transcriptomic data.

Clinical Implications

Understanding the relationship between dynamic gene expression and patient outcomes could enhance prognostic assessments.

Conclusion

This study provides a new perspective on melanoma progression and immune interactions.

Related Resources & Content

1. Aung et al, Clinical Cancer Research, 2024 -- Novel Spatial Gene-Signature Approach May Help to Predict Immunotherapy Outcomes in Patients With Melanoma
2. The Pathologist, 2026 -- A New Molecular Barcode for Cancer?
3. The ASCO Post, 2025 -- Spatial Transcriptomics Identifies Novel Subtypes Associated With Disease Prognosis in Leiomyosarcoma
4. The Pathologist, 2026 -- Blood Test Predicts Immunotherapy Response
5. European Journal of Cancer, 2025 -- Current guideline landscape and staging
6. New England Journal of Medicine, 2024 -- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
7. PubMed -- Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort
8. European Journal of Cancer 215 (2025) 115153
9. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma | New England Journal of Medicine
10. Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort - PubMed